Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9NZU0: Variant p.Glu97Gly

Leucine-rich repeat transmembrane protein FLRT3
Gene: FLRT3
Feedback?
Variant information Variant position: help 97 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Glutamate (E) to Glycine (G) at position 97 (E97G, p.Glu97Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and acidic (E) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In HH21; patients have a second mutation in another HH-associated gene including FGFR1, HS6ST1 and FGF17. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 97 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 649 The length of the canonical sequence.
Location on the sequence: help SDLKNLLKVERIYLYHNSLD E FPTNLPKYVKELHLQENNIR The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         SDLKNLLKVERIYLYHNSLDEFPTNLPKYVKELHLQENNIR

Mouse                         SDLKNLLKVQRIYLYHNSLDEFPTNLPKYVKELHLQENNIR

Rat                           SDLKNLLKVQRIYLYHNSLDEFPTNLPKYVKELHLQENNIR

Chicken                       SELKNLRRVERIFLYHNSLDEFPTNLPKYVKELHLQENNIR

Xenopus laevis                SDLKGLDKVERIYLYRNSLDEFPINLPKNVKELHLQENNIR

Xenopus tropicalis            SDLRGLDKVERIYLYRNSLDEFPINLPKNVKELHLQENNIR

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 29 – 649 Leucine-rich repeat transmembrane protein FLRT3
Topological domain 29 – 528 Extracellular
Repeat 84 – 104 LRR 2
Mutagenesis 89 – 89 Y -> A. Abolishes ADGRL3 binding; when associated with A-91.
Mutagenesis 91 – 91 Y -> A. Abolishes ADGRL3 binding; when associated with A-89.



Literature citations
Mutations in FGF17, IL17RD, DUSP6, SPRY4, and FLRT3 are identified in individuals with congenital hypogonadotropic hypogonadism.
Miraoui H.; Dwyer A.A.; Sykiotis G.P.; Plummer L.; Chung W.; Feng B.; Beenken A.; Clarke J.; Pers T.H.; Dworzynski P.; Keefe K.; Niedziela M.; Raivio T.; Crowley W.F. Jr.; Seminara S.B.; Quinton R.; Hughes V.A.; Kumanov P.; Young J.; Yialamas M.A.; Hall J.E.; Van Vliet G.; Chanoine J.P.; Rubenstein J.; Mohammadi M.; Tsai P.S.; Sidis Y.; Lage K.; Pitteloud N.;
Am. J. Hum. Genet. 92:725-743(2013)
Cited for: VARIANTS HH21 LYS-69; GLY-97; ILE-144 AND ARG-339;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.